L'Agence européenne des médicaments (EMA) enquête sur des rapports sur le vaccin Covid-19 d'AstraZeneca causant le syndrome de Guillain-Barre, alors que la société pharmaceutique reste impliquée dans une controverse sur le lien du vaccin avec la coagulation sanguine. </p><div><p>Lors d'une réunion cette semaine, le comité d'évaluation des risques de pharmacovigilance (PRAC) de l'Agence européenne des médicaments a révélé qu'il <em>«Évaluer les rapports»</em> des troubles rares du système immunitaire observés chez les personnes suivant la vaccination.
“As part of the review of periodic safety summary reports on the Vaxzevria pandemic, AstraZeneca’s Covid-19 vaccine, the PRAC analyzes the data provided by the marketing authorization holder on cases of Guillain-Barré syndrome (GBS) reported following vaccination “, said the PRAC.
Also on rt.com
Quelques preuves '' Plus de femmes que d'hommes ont des caillots sanguins rares avec AstraZeneca Covid-19 jab, mais la différence est petite » – UK Drug Regulator
“GBS was identified during the marketing authorization process as a possible adverse event requiring specific safety monitoring activities”, continued the committee, adding that it had asked “More detailed data” on the cases and will post new information as it becomes available.
According to the UK’s National Health Service (NHS), Guillain-Barré syndrome is a “Very rare and serious condition affecting the nerves”, and can create feelings of numbness, weakness and pain in those who have it.
Although the NHS advises that Guillain-Barre syndrome is a treatable disease and that “Most people will eventually make a full recovery”, it can also be life threatening and leave those who have had it “Long-term problems”
After hundreds of cases of blood clotting – and dozens of deaths – AstraZeneca’s Covid-19 vaccine has already been restricted in many countries to the elderly only.
In the UK, people under 40 will be offered an alternative vaccine provided it does not result in any «Retards» in the vaccination program, however, the European Medicines Agency argues that the benefits of the vaccine outweigh the risk for much of the population.
Also on rt.com
The British vaccination committee says that those under 40 should opt for an alternative to AstraZeneca linked to a blood clot …
Do you think your friends would be interested? Share this story!